Revenue: As of FY2025 Q1, the actual value is USD 517 K.

EPS: As of FY2025 Q1, the actual value is USD 0.28.

Segment Revenue

• Product Revenue, Net: $147,000 for the three months ended March 31, 2025.
• Contract Revenue: $370,000 for the three months ended March 31, 2025.

Operational Metrics

• Net Income: $39,139,000 for the three months ended March 31, 2025, compared to a net loss of $31,896,000 for the same period in 2024.
• Loss from Operations: - $23,184,000 for the three months ended March 31, 2025, compared to - $26,578,000 for the same period in 2024.
• Research and Development Expenses: $15,418,000 for the three months ended March 31, 2025, a decrease from $21,264,000 for the same period in 2024.
• Selling, General and Administrative Expenses: $8,136,000 for the three months ended March 31, 2025, an increase from $5,314,000 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $28,601,000 for the three months ended March 31, 2025, compared to - $27,347,000 for the same period in 2024.
• Net Cash Used in Investing Activities: - $228,000 for the three months ended March 31, 2025, compared to - $391,000 for the same period in 2024.
• Net Cash Provided by Financing Activities: $46,739,000 for the three months ended March 31, 2025, compared to $62,795,000 for the same period in 2024.

Unique Metrics

• Change in Fair Value of Contingent Earnout Liability: $49,731,000 gain for the three months ended March 31, 2025, compared to a - $4,593,000 loss for the same period in 2024.
• Change in Fair Value of Derivatives: $14,930,000 gain for the three months ended March 31, 2025, compared to a $60,000 gain for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to commercialize Symvess in the U.S. for vascular trauma and, if approved, in AV access for hemodialysis. It aims to obtain marketing approval for its 6 millimeter ATEV in additional indications and scale its manufacturing facility to meet market demand.
• Non-Core Business: The company is exploring applications of its technology across a broad range of markets and indications, including the development of urinary conduit, trachea, esophagus, and other novel cell delivery systems.
• Priority: The company estimates savings from workforce and other operating cost reductions, and reduced capital expenditures, totaling approximately $13.8 million in 2025 and up to approximately $38.0 million in 2026.